Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect

This publication has 20 references indexed in Scilit:

• Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation
  Blood, 2002
• Role of Nonmyeloablative Allogeneic Stem-Cell Transplantation After Failure of Autologous Transplantation in Patients With Lymphoproliferative Malignancies
  Journal of Clinical Oncology, 2002
• Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial
  The Lancet, 2002
• Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison ofhigh-dose conventional conditioning versusfludarabine-based reduced-intensity regimens
  Annals of Oncology, 2002
• Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma
  Annals of Hematology, 2002
• Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM–CAMPATH (± fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion
  Cytotherapy, 2001
• Reduced-intensity allogeneic stem cell transplantation as salvage treatment for patients with indolent lymphoma or CLL after failure of autologous SCT
  Bone Marrow Transplantation, 2000
• BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors
  Bone Marrow Transplantation, 1997
• Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
  New England Journal of Medicine, 1995
• Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide.
  Journal of Clinical Oncology, 1993